| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.4 | 0.004 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | 0.54 | 0.004 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.004 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.006 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.093 | 0.006 |
| mRNA | AZD0530 | FIMM | pan-cancer | AAC | 0.47 | 0.006 |